RLMD
Neutral signalScored 2026-10-04 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Relmada Therapeutics, Inc.
- Nom
- Relmada Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $348.8M
- Employés
- 17
- PDG
- Sergio Traversa
- Site web
- https://www.relmada.com
- Marché
- ACETACRVCBUSFBIOIMUXLITS
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 200 000 titres (~828 000,00 $ US)
- Insiders
- TRAVERSA SERGIO
- Total bought
-
$828,000
Avg buy (VWAP, 90d window) $4.18 vs last close $3.39 (-18.9%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-10
- Liquidity
- Thin $4,315,912/day · 20d vol
- Last synced
-
2026-10-11 09:40:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-10 | Shenouda Maged | Buy · P | 79,800 | $4.25 | $339,150 | Form 4 |
| 2026-09-10 | TRAVERSA SERGIO | Buy · P | 100,000 | $4.10 | $410,000 | Form 4 |
| 2026-09-09 | Shenouda Maged | Buy · P | 120,200 | $4.20 | $504,840 | Form 4 |
| 2026-09-09 | TRAVERSA SERGIO | Buy · P | 100,000 | $4.18 | $418,000 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Chris Jacobs | Sale (Full) | $1,001 - $15,000 |
| 2022-11-08 | Chris Jacobs | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-04 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
RLMD presents a mixed profile: a meaningful insider cluster buy (~$828k) by a key executive signals strong internal conviction, and positive biotech recovery sentiment adds narrative tailwind, but the company is…
The first sentence of the analysis written for RLMD on 2026-10-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 14.62 · operating margin 0.0%
Suggested stop 3.11, nearest stored support minus 0.5 ATR(8.1% under the last close). Reward/risk to the next stored resistance is 1.55. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 14.615 | 4.450 | 7.996 | 12.260 | 14.826 | |
| Quick Ratio | 14.615 | 4.450 | 7.996 | 12.260 | 14.826 | |
| Solvency Ratio | -7.660 | -7.768 | 0.403 | -12.595 | -8.349 | |
| Cash Ratio | 0.544 | 0.375 | 0.336 | 0.433 | 2.951 | |
| Price To Earnings Ratio | -3.331 | -0.196 | -0.314 | -0.165 | -0.630 | |
| Price To Earnings Growth Ratio | 0.074 | 0.010 | 0.008 | 0.006 | -0.007 | |
| Forward Price To Earnings Growth Ratio | 0.074 | 0.010 | 0.008 | 0.006 | -0.007 | |
| Price To Earnings Diluted Ratio | -3.331 | -0.196 | -0.314 | -0.165 | -0.630 | |
| Price To Earnings Diluted Growth Ratio | 0.074 | 0.010 | 0.008 | 0.006 | -0.007 | |
| Price To Book Ratio | 2.204 | 0.442 | 0.363 | 0.184 | 0.380 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -4.165 | -0.303 | -0.600 | -0.249 | -0.862 | |
| Price To Operating Cash Flow Ratio | -4.165 | -0.303 | -0.600 | -0.249 | -0.862 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.087 | 1.290 | 1.143 | 1.089 | 1.072 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -7.120 | -5.029 | -4.236 | -8.325 | -6.100 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | -12,914,801.500 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | -12,914,801.500 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.262 | -0.148 | 5.481 | -0.130 | -0.276 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 14.615 | ▲10.165 | ▲3.786 |
| Quick Ratio | 14.615 | ▲10.165 | ▲3.786 |
| Solvency Ratio | -7.660 | ▲0.108 | ▼-0.466 |
| Cash Ratio | 0.544 | ▲0.169 | ▼-0.384 |
| Price To Earnings Ratio | -3.331 | ▼-3.135 | ▼-2.404 |
| Price To Earnings Growth Ratio | 0.074 | ▲0.063 | ▲0.055 |
| Forward Price To Earnings Growth Ratio | 0.074 | ▲0.063 | ▲0.055 |
| Price To Earnings Diluted Ratio | -3.331 | ▼-3.135 | ▼-2.404 |
| Price To Earnings Diluted Growth Ratio | 0.074 | ▲0.063 | ▲0.055 |
| Price To Book Ratio | 2.204 | ▲1.763 | ▲1.490 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -4.165 | ▼-3.862 | ▼-2.929 |
| Price To Operating Cash Flow Ratio | -4.165 | ▼-3.862 | ▼-2.929 |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.087 | ▼-0.203 | ▼-0.050 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -7.120 | ▼-2.091 | ▼-0.958 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | 0.000 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲2582960.300 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲2582960.300 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.262 | ▼-3.114 | ▼-3.595 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $190.7M | $15.7M | $31.0M | $25.9M | $79.2M | |
| Enterprise value | $187.2M | $11.8M | $26.9M | $20.5M | $34.7M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -4.09x | -0.23x | -0.52x | -0.20x | -0.38x | |
| EV / Free cash flow | -4.09x | -0.23x | -0.52x | -0.20x | -0.38x | |
| EV / EBITDA | -3.26x | -0.15x | 5.48x | -0.13x | -0.28x | |
| Net debt / EBITDA | 0.06x | 0.05x | -0.83x | 0.03x | 0.35x | |
| Current ratio | 14.62x | 4.45x | 8.00x | 12.26x | 14.83x | |
| Income quality | 0.80x | 0.65x | 0.52x | 0.66x | 0.73x | |
| Graham net-net | $2 | $1 | $3 | $5 | $11 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $87.6M | $35.5M | $85.3M | $140.4M | $208.2M | |
| Invested capital | $87.6M | $35.5M | $85.3M | $140.4M | $208.2M | |
| Return on assets | -61.0% | -174.6% | -101.3% | -102.7% | -56.3% | |
| Operating ROA | -84.5% | -117.0% | -82.8% | -85.7% | -73.6% | |
| Return on tangible assets | -61.0% | -174.6% | -101.3% | -102.7% | -56.3% | |
| Return on equity | -66.3% | -225.2% | -115.7% | -111.8% | -60.4% | |
| Return on invested capital | -67.5% | -236.1% | -121.5% | -114.8% | -60.4% | |
| Return on capital employed | -67.5% | -236.1% | -121.5% | -114.8% | -60.4% | |
| Earnings yield | -30.1% | -509.9% | -318.7% | -607.5% | -158.9% | |
| Free cash flow yield | -24.0% | -330.0% | -166.6% | -401.5% | -116.1% | |
| Capex / Op. cash flow | 0.0% | 0.0% | -0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-14 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
- 2026-09-01 Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026.
- 2026-08-31 After Plunging 18.5% in 4 Weeks, Here''s Why the Trend Might Reverse for Relmada Therapeutics (RLMD) Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 2026-08-25 Here''s Why Relmada Therapeutics (RLMD) Is a Great ''Buy the Bottom'' Stock Now Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock''s potential for a turnaround in the near term.
- 2026-08-11 Down 29.6% in 4 Weeks, Here''s Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 2026-08-07 Relmada Therapeutics Q2 Earnings Call Highlights Relmada Therapeutics NASDAQ: RLMD said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026.
- 2026-08-07 Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript
- 2026-08-04 Critical Review: Relmada Therapeutics (NASDAQ:RLMD) versus Novo Nordisk A/S (NYSE:NVO) Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Novo Nordisk A/S (NYSE: NVO - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership. Volatility and Risk Relmada Therapeutics has a
- 2026-07-29 ADAR1 Capital Management LLC Grows Stock Position in Relmada Therapeutics, Inc. $RLMD ADAR1 Capital Management LLC increased its holdings in Relmada Therapeutics, Inc. (NASDAQ: RLMD) by 1,364.1% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 451,918 shares of the company''s stock after acquiring an additional 421,052 shares during the period. ADAR1 Capital Management LLC owned approximately 0.43%
- 2026-07-28 Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Bipin Dalmia, PhD, MBA, as Chief Business Officer. Bipin will lead Relmada''s corporate strategy, commercial planning, and business development activities, reporting directly to Chief Executive Officer Sergio Traversa.